March 28, 2019 09:39 AM EDTUpdated 02:02 PM
People

Sure Hervé Hop­penot took a big cut in com­pen­sa­tion af­ter a pipeline dis­as­ter. But he still outscored the on­ly woman on the list

John Carroll

Editor & Founder

Af­ter a bru­tal year at the helm, In­cyte CEO Hervé Hop­penot took a big cut in an­nu­al com­pen­sa­tion for 2018 — but he still made more than GSK CEO Em­ma Walm­s­ley.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times